Your browser doesn't support javascript.
loading
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Hugo, Willy; Zaretsky, Jesse M; Sun, Lu; Song, Chunying; Moreno, Blanca Homet; Hu-Lieskovan, Siwen; Berent-Maoz, Beata; Pang, Jia; Chmielowski, Bartosz; Cherry, Grace; Seja, Elizabeth; Lomeli, Shirley; Kong, Xiangju; Kelley, Mark C; Sosman, Jeffrey A; Johnson, Douglas B; Ribas, Antoni; Lo, Roger S.
Afiliação
  • Hugo W; Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Zaretsky JM; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Sun L; Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Song C; Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Moreno BH; Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Hu-Lieskovan S; Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Berent-Maoz B; Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Pang J; Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Chmielowski B; Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Cherry G; Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Seja E; Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Lomeli S; Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Kong X; Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA.
  • Kelley MC; Department of Surgery, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.
  • Sosman JA; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.
  • Johnson DB; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.
  • Ribas A; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1662, USA; Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; Division of Surgical Oncology, Department of Surgery, University of C
  • Lo RS; Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 9009
Cell ; 165(1): 35-44, 2016 Mar 24.
Article em En | MEDLINE | ID: mdl-26997480
ABSTRACT
PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identify factors that may influence innate sensitivity or resistance to anti-PD-1 therapy. We find that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2. Innately resistant tumors display a transcriptional signature (referred to as the IPRES, or innate anti-PD-1 resistance), indicating concurrent up-expression of genes involved in the regulation of mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing. Notably, mitogen-activated protein kinase (MAPK)-targeted therapy (MAPK inhibitor) induces similar signatures in melanoma, suggesting that a non-genomic form of MAPK inhibitor resistance mediates cross-resistance to anti-PD-1 therapy. Validation of the IPRES in other independent tumor cohorts defines a transcriptomic subset across distinct types of advanced cancer. These findings suggest that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Melanoma / Anticorpos Monoclonais / Metástase Neoplásica / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Melanoma / Anticorpos Monoclonais / Metástase Neoplásica / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article